

Eli Lilly and Company (LLY)

Healthcare / Drug Manufacturers - General · New York Stock Exchange

Generated: 2026-Oct-18 · Market data through: 2026-10-16

LAST CLOSE \$1257.03 2026-10-16	MARKET CAP \$1.18T VOLUME 2.4M	52-WK HIGH \$1292.65 52-WK LOW \$783.85	TRAILING PE 42.1 P/S 14.85	GROSS MARGIN 83.4% NET MARGIN 33.5%	ROE 93% ROIC 31%	PIOTROSKI 8/9 ALTMAN Z 8.5	1-YR RETURN +53.6% 5-YR RETURN +1124.2%
--	---	--	---	--	---	---	--

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

SECTOR Healthcare INDUSTRY Drug Manufacturers - General EXCHANGE NYSE MARKET CAP \$1.18T EMPLOYEES 50,000 (SEC-filed) CEO David A. Ricks
IPO 1972-06-01 COUNTRY US
Lilly Corporate Center, Indianapolis, IN 46285 · Tel 317 276 2000 · [lilly.com](https://www.lilly.com)

1 INSIDERSTREET SCORE

INSIDERSTREET SCORE

78 / 100

Street mean **\$1342.90** (10 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNAL


ROUTINE SELLING — LOW SIGNAL

\$35M sold / 6 mo, zero open-market buys


2 PRICE AND VOLUME

adjusted close, prod data layer

1 Year vs S&P 500 · **LLY +53.6%** · **S&P 500 +15.9%** · spread **+37.8pp**



7 Years vs S&P 500 · **LLY +1124.2%** · **S&P 500 +189.9%** · spread **+934.4pp**



Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

3 INSIDERSTREET SCORE live IS factor model

INSIDERSTREET
SCORE
78
OF 100

Score Breakdown

Profitability	100/100
Growth	88/100
Momentum	94/100
Quality	84/100
Earnings Quality	67/100
Balance Sheet	54/100
Value	37/100
Risk (safety)	100/100
Overall	77.7/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is **not** the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

SYMBOL	IS SCORE
JNJ	64
ABBV	67
MRK	49
NVS	65
AZN	71
AMGN	67
LLY	78

IS Score Trend — quarterly



14 quarters, 23 Q1 to 26 Q2. Peak 78 in 26 Q2, latest 78 — +0 since. Fell in 1 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

4 TWO READINGS business vs price

BUSINESS QUALITY
78 / 100

IS Score 77.7 / 100 · +0.0 from peak of 78

Quarter	Business Quality
23 Q1	52
23 Q2	58
23 Q3	46
23 Q4	46
24 Q1	52
24 Q2	53
24 Q3	62
24 Q4	60
25 Q1	61
25 Q2	72
25 Q3	73
25 Q4	72
26 Q1	78

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURE
BULLISH

Technical Score 90 / 100 · Power +80 · 22 of 22 indicator votes bullish

Date	Price Structure
07-23	44%
08-13	80%
09-03	35%
09-25	13%
10-16	105%

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 78 and price structure at 90 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

5 WHAT WOULD CHANGE OUR MIND falsifiable - check us next quarter

TRIGGER	WHERE IT STANDS NOW	WHAT IT WOULD MEAN
IS Score reaches 75 and holds two consecutive quarters	now 77.7	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 72 → 73 → 73 → 78	the direction matters more than the level
Technical vote share back above 50%	now 100%	price structure no longer broken
Institutional holder count rises two quarters running	peak 4,653 → now 4,653	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

6 SMART MONEY CONFLUENCE

EDGE · disclosure sources


SITE CONVERGENCE SCORE 3 of 4 top 4% of 29,420 symbols	SOURCES ALIGNED — of 3 independent disclosures	CONGRESS (180D) 5 buys 2026-09-04	INSIDER BUYS (180D) 0 none disclosed
ETF FUNDS (30D) 2149 up / 1821 down net +328 funds	INSTITUTIONS ADDED (13F) 262 managers opening or increasing		

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

7 INSTITUTIONAL OWNERSHIP - 12-QUARTER TREND

13F · filed 45 days after quarter end

Institutions holding — 12 quarters



Peak 4,653 · latest 4,653 (+0 from peak).

QUARTER	HOLDERS	13F SHARES	VALUE	REPORTED OWN%
2026 Q2	4,653	793.5M	\$925.0B	88.9%
2026 Q1	4,391	776.4M	\$694.3B	87.0%
2025 Q4	4,455	789.6M	\$820.1B	88.5%
2025 Q3	3,906	765.3M	\$569.1B	85.8%
2025 Q2	3,920	783.8M	\$592.8B	87.8%
2025 Q1	3,932	836.6M	\$669.5B	93.8%
2024 Q4	3,914	781.6M	\$582.9B	87.6%
2024 Q3	3,669	790.1M	\$665.0B	88.5%
2024 Q2	3,574	781.6M	\$683.5B	87.6%
2024 Q1	3,471	782.7M	\$586.9B	87.7%
2023 Q4	3,282	784.4M	\$442.2B	87.9%
2023 Q3	2,982	785.8M	\$408.2B	88.0%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY


8 INSIDER ACTIVITY live Form 4 data

INSIDER	ROLE	DATE	TYPE	SHARES	VALUE	POST-TXN OWNED
Luciano Juan R	director	2026-09-21	A-Award	14	\$0.02M	16,957
Fyrwald J Erik	director	2026-09-21	A-Award	9	\$0.01M	75,536
Alvarez Ralph	director	2026-09-21	A-Award	11	\$0.01M	55,838
Sulzberger Gabrielle	director	2026-09-21	A-Award	4	\$0.00M	3,012
Seymour Melissa	EVP, Global Quality	2026-09-09	GIFT	12	—	1,038
Hernandez Edgardo	EVP & Pres., Mfg. Operations	2026-09-02	GIFT	13	—	46,083
Dozier Eric	EVP, Chief People Officer	2026-09-02	GIFT	216	—	14,239
Sulzberger Gabrielle	director	2026-08-17	A-Award	4	\$0.00M	3,004

9 SELL DECOMPOSITION — ROUTINE VS. DISCRETIONARY EDGE

6-MO DECOMPOSITION (FORM 4)	TXNS	SHARES	VALUE	SIGNAL WEIGHT
S — Open-market sales	6	31,828	\$34.6M	Counted
M — Exercises (paired A/D)	1	981	—	None — mechanics
F — Tax withholding	1	439	\$0.5M	None — compensation
G — Gifts	3	241	—	None
P — Open-market purchases	0	0	\$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)



Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SIGNAL Routine Selling — Low Signal	OPEN-MARKET SELLS \$34.6M 6 txns / 6 mo	OPEN-MARKET BUYS \$0.0M 0 txns / 6 mo	CLUSTER None active 3+ insiders / 21 days
---	--	--	--

10 FORM 144 PLANNED-SALE PIPELINE live EDGAR data

FILED	FILER	SHARES REGISTERED	EST. PROCEEDS
2026-10-15	Lilly Endowment, Inc.	305,000	\$368.7M
2026-10-07	Lilly Endowment, Inc.	300,000	\$347.2M
2026-08-17	Patrik Jonsson	6,500	\$7.6M
2026-08-10	Donald Zakrowski	2,000	\$2.4M
Trailing 12 mo	26 filings	6,298,000	\$6233M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

11 13D / 13G STAKES				COND
FILED	FORM	REPORTING PERSON	% OF CLASS	SHARES
2026-07-23	SCHEDULE 13G/A	LILLY ENDOWMENT, INC.	9.60%	90.4M sh
2026-05-01	SCHEDULE 13G	Vanguard Capital Management	6.48%	61.3M sh
2026-04-20	SCHEDULE 13G/A	LILLY ENDOWMENT, INC.	9.70%	91.9M sh
2026-01-23	SCHEDULE 13G/A	LILLY ENDOWMENT, INC.	9.80%	92.2M sh

12 CONGRESSIONAL TRADING				EDGE · STOCK Act	
MEMBER	CHAMBER	TRADE	SIZE BAND	TRADED	DISCLOSED
Ro Khanna	House	BUY	\$1,001 - \$15,000	2026-09-04	2026-10-09
Dan Newhouse	House	SELL	\$1,001 - \$15,000	2026-07-10	2026-07-20
Daniel Milton Newhouse	House	SELL	\$1,001 - \$15,000	2026-07-10	2026-07-20
Alan Armstrong	Senate	SELL	\$1,001 - \$15,000	2026-03-27	2026-07-20
Angus King	Senate	SELL	\$1,001 - \$15,000	2026-02-13	2026-03-24
Angus Stanley King	Senate	SELL	\$1,001 - \$15,000	2026-02-13	2026-03-24
HOUSE 12-MO 51 trades 22 purchases		SENATE 12-MO 22 trades 12 purchases		COVERAGE STOCK Act filings 30-45 day disclosure lag	


13 INSTITUTIONAL OWNERSHIP & 13F FLOW				live 13F data
13F FILERS (LAST COMPLETE Q) 4,391	13F SHARES 776M 87.0% of shares out	NEW / CLOSED 242 / 228 positions, QoQ	INCREASED / REDUCED 1,952 / 1,703 positions, QoQ	
PUT/CALL (13F) 1.17 option positions	FREE FLOAT 90.1% 848M sh			

2.8 · Largest Reporting 13F Managers

MANAGER	SHARES	VALUE
Sapient Capital Llc	1.5M	\$1.7B
Assenagon Asset Management S.A.	784,936	\$908M
Goelzer Investment Management, Inc	556,177	\$644M
Private Capital Advisors, Inc.	411,540	\$476M
Ninety One Uk Ltd	344,968	\$399M
Fjarde Ap-Fonden /Fourth Swedish N	255,175	\$295M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.


13F Filers Holding LLY — quarterly



2.9 · Top ETF & Fund Ownership

FUND	WEIGHT	POSITION
VITSX	1.3%	\$31.1B
VTSAX	1.3%	\$31.1B
VTI	1.3%	\$31.1B
VSMPX	1.3%	\$31.1B
VOO	1.4%	\$24.3B
VFFSX	1.4%	\$24.3B


Institutional Put/Call — quarterly



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

14 SHORT VOLUME — DAILY, 60 SESSIONS


EDGE · live FINRA feed



LATEST SESSION 40.5% 2026-10-15	20-DAY AVG 47.9% 50-day 44.9%	TREND Rising 20d vs 50d	BY MARKET CENTER Q: 40% · N: 57% · B: 36% latest session
--	--	--------------------------------------	---

15 DARK POOL ACTIVITY


EDGE · live ATS data



Where LLY Trades in the Dark		
ATS VENUE (4-WK)	SHARES	AVG TRADE
Ubsa Ubs Ats	3.0M	28 sh
Incr Intelligent Cross Llc	2.9M	24 sh
Sgmt Sigma X2	1.7M	23 sh
Mlix Instinct X	1.3M	36 sh
Ebxl Level Ats	1.1M	14 sh
Mspl Ms Pool (Ats - 4)	1.0M	83 sh

16 REVENUE FLOW — FY2025

live segmentation + income data



Where a dollar of Eli Lilly and Company revenue goes. All values FY2025 filings, live.

17 GEOGRAPHIC REVENUE

live segmentation


REGION	REVENUE	SHARE
UNITED STATES	\$43.5B	67%
Europe	\$11.6B	18%
Non-US	\$6.1B	9%
JAPAN	\$2.1B	3%
CHINA	\$2.0B	3%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

18 MOAT & COMPETITIVE POSITION


LIVE MODEL · 86/100 WIDE

Moat score 86/100 — Wide; primary source Efficient Scale.



■ LLY (live moat model) ■ Peer median: JNJ · ABBV · MRK · NVS · AZN

3.8 · Employees (SEC filings)





19 CORPORATE INFORMATION — KEY OFFICERS

50,000 employees

OFFICER	TITLE
David A. Ricks	Chairman, Chief Executive Officer & President
Daniel Skovronsky	Chief Scientific & Product Officer and President of Lilly Research Laboratories
Anat Hakim	Executive Vice President, General Counsel & Secretary
Lucas E. Montarce	Executive Vice President & Chief Financial Officer

20 REVENUE & EPS — HISTORY AND ESTIMATES

live consensus




Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

21 ESTIMATE VS. ACTUAL & SURPRISES

live data



22 REPORTED VS. CONSENSUS — FULL HISTORY

0 quarters · live data


BEAT RATE —% 0 of 0 quarters	CURRENT STREAK 0 longest 0	AVG EPS SURPRISE —% median —%	SURPRISE TREND — last 4 vs prior 4
------------------------------------	----------------------------------	-------------------------------------	--

PERIOD	EPS EST.	EPS ACTUAL	EPS SURPRISE	REV EST. (\$M)	REV ACTUAL (\$M)	REV SURPRISE
--------	----------	------------	--------------	----------------	------------------	--------------

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.


INCOME TRENDS — 5 YEAR

live financials



NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked



Live segmentation data.

YoY Growth Heatmap — Income Lines

YOY GROWTH	FY21	FY22	FY23	FY24	FY25
Revenue	+15.4%	+0.8%	+19.6%	+32.0%	+44.7%
Gross profit	+10.2%	+4.3%	+23.4%	+35.4%	+49.1%
Operating income	+10.0%	+9.1%	+24.7%	+62.2%	+69.7%
Net income	-9.9%	+11.9%	-16.1%	+102.1%	+94.9%


23 INCOME STATEMENT — FULL						live financials
\$B · FY ENDS	FY21	FY22	FY23	FY24	FY25	TREND
Revenue	28.3	28.5	34.1	45.0	65.2	
Cost of revenue	7.3	6.6	7.1	8.4	10.6	
Gross profit	21.0	21.9	27.0	36.6	54.6	
R&D expense	6.9	7.2	9.3	11.0	13.3	
SG&A expense	6.1	6.1	6.9	8.1	11.1	
Operating income	7.9	8.7	10.8	17.5	29.7	
EBITDA	8.0	8.7	8.6	15.2	27.9	
D&A	1.5	1.5	1.5	1.8	1.6	
Pretax income	6.2	6.8	6.6	12.7	25.7	
Income tax	0.6	0.6	1.3	2.1	5.1	
Net income	5.6	6.2	5.2	10.6	20.6	
Diluted EPS (\$)	5.85	6.57	5.80	11.71	22.95	
Diluted shares (M)	954	950	903	904	898	

CASH FLOW TRENDS						live data
OPERATING CF	CAPEX	FREE CASH FLOW	SBC	BUYBACKS	NET CASH CHANGE	
 \$17B	 \$8B	 \$9B	 \$1B	 \$4B	 \$4B	

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

WHERE THE CASH WENT — FY2025

cash Sankey, live data



Balance Sheet — Full


\$B	FY22	FY23	FY24	FY25	
Cash & equivalents	2.1	2.8	3.3	7.2	
ST investments	0.1	0.1	0.2	0.1	
Receivables (net)	8.6	11.3	13.3	20.2	
Total current assets	18.0	25.7	32.7	55.6	
PP&E (net)	10.1	12.9	17.1	24.7	
Goodwill + intangibles	11.3	11.8	11.9	12.4	
Total assets	49.5	64.0	78.7	112.5	
Accounts payable	1.9	2.6	3.2	5.4	
Short-term debt	1.5	6.9	5.1	1.6	
Deferred revenue	0.0	0.0	0.0	0.0	
Total current liabilities	17.1	27.3	28.4	35.2	
Long-term debt	14.7	18.3	28.5	40.9	
Total liabilities	38.7	53.1	64.4	85.9	
Shareholders' equity	10.8	10.9	14.3	26.5	

Cash Flow Statement — Full

\$B	FY22	FY23	FY24	FY25	
Net income	6.2	5.2	10.6	20.6	
D&A	1.5	1.5	1.8	2.0	
Stock-based compensation	0.4	0.6	0.6	0.6	
Working capital change	(0.0)	(3.1)	(5.4)	(8.1)	
Operating cash flow	7.6	4.2	8.8	16.8	
Capital expenditures	(3.0)	(7.4)	(8.4)	(7.8)	
Investing cash flow	(3.8)	(7.2)	(9.3)	(11.0)	
Buybacks	(1.5)	(0.8)	(2.5)	(4.1)	
Dividends paid	(3.5)	(4.1)	(4.7)	(5.4)	
Debt issuance / (repay)	(0.1)	8.6	8.9	8.1	
Financing cash flow	(5.4)	3.5	1.2	(2.2)	
Free cash flow	4.6	(3.2)	0.4	9.0	

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY



24 EXPANDED RATIO ANALYSIS (I)

live ratio engine · profitability · valuation

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
PROFITABILITY							
ROE	76.4%	63.6%	48.9%	84.8%	101.3%	93%	
ROA	11.7%	12.7%	9.2%	14.8%	21.6%	18.8%	
ROIC	32.5%	32.2%	26.1%	32.9%	38.6%	31.0%	
Gross margin	74.2%	76.8%	79.2%	81.3%	83.8%	83.4%	
Operating margin	28.0%	30.3%	31.6%	38.9%	45.6%	49.7%	
Net margin	19.7%	21.9%	15.4%	23.5%	31.7%	33.5%	
EBITDA margin	28.4%	30.3%	25.1%	33.8%	42.9%	54.4%	
FCF margin	19.0%	16.1%	-9.2%	1.1%	13.8%	—	
VALUATION							
P/E	45.46	54.36	99.16	65.35	46.76	42.1	
P/B	28.26	31.87	48.24	48.77	36.37	33.1	
P/S	8.96	11.89	15.23	15.36	14.81	14.85	
P/FCF	47.10	73.79	-164.86	1354.90	107.56	59.0	
EV/EBITDA	33.17	40.82	63.25	47.43	35.81	28.4	
EV/Revenue	9.42	12.38	15.88	16.04	15.35	15.4	
Earnings yield	2.2%	1.8%	1.0%	1.5%	2.1%	2.38%	
FCF yield	2.1%	1.4%	-0.6%	0.1%	0.9%	1.69%	

EXPANDED RATIO ANALYSIS (II)

leverage · solvency

RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
LEVERAGE & SOLVENCY							
Current ratio	1.23	1.05	0.94	1.15	1.58	1.35	
Quick ratio	0.97	0.80	0.73	0.89	1.19	1.00	
Debt / equity	1.88	1.52	2.34	2.37	1.60	1.62	
Debt / assets	34.6%	32.8%	39.4%	42.7%	37.8%	38.6%	
Net debt / EBITDA	1.61	1.62	2.60	1.98	1.26	1.06	
Interest coverage	19.12	21.53	14.49	17.24	33.16	—	

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

EXPANDED RATIO ANALYSIS (III)							efficiency · growth · per-share · scores
RATIO	FY21	FY22	FY23	FY24	FY25	TTM	TREND
EFFICIENCY							
Asset turnover	0.59	0.58	0.60	0.63	0.68	0.56	
Receivables turnover	4.51	4.21	4.27	4.48	4.53	3.4	
DSO (days)	81	87	85	81	81	108	
DPO (days)	82	99	117	126	149	169	
Cash conversion cycle	195	213	229	245	300	402	
GROWTH (YoY)							
Revenue growth	15.4%	0.8%	19.6%	32.0%	44.7%	—	
Net income growth	-9.9%	11.9%	-16.1%	102.1%	94.9%	—	
EPS growth	-9.6%	12.3%	-11.8%	102.3%	96.0%	—	
FCF growth	20.2%	-14.6%	-168.5%	116.2%	1656.5%	—	
PER SHARE (\$)							
EPS (diluted, TTM)	5.85	6.57	5.80	11.73	22.98	29.93	
Book value / share	9.42	11.21	11.92	15.71	29.55	37.96	
Revenue / share	29.69	30.04	37.75	49.87	72.58	89.27	
FCF / share	5.65	4.84	-3.49	0.57	9.99	22.47	
Cash / share	4.10	2.33	3.24	3.79	8.09	10.03	
SHAREHOLDER RETURN & SCORES							
Buyback yield	0.5%	0.4%	0.1%	0.4%	0.4%	0.58%	
Altman Z-Score	5.20	6.62	6.96	7.89	8.61	8.5	
Piotroski F-Score	6	8	5	7	8	8/9	
Beneish M-Score	-2.45	-2.59	-2.08	-2.11	-1.89	-2.01	

25 EARNINGS QUALITY PANEL				live scores
MODEL	SCORE	ZONE	NOTE	
Piotroski F-Score	8 / 9	Strong		
Altman Z-Score	8.5	Safe (>2.99)	Safe	
Income quality	1.05	Cash-backed	OCF ÷ net income	
Beneish M-Score	-2.01	Elevated	vs -2.22 threshold	

26 DUPONT & GROWTH QUALITY				live analysis engine
DUPONT DECOMPOSITION (TTM)		VALUE	GROWTH QUALITY (LIVE)	VALUE
Tax burden		0.80	Revenue stability	0.79
Interest burden		0.89	Earnings stability	0.69
Operating margin		47.6%	Earnings persistence	0.50
Asset turnover		0.66×	Revenue CAGR 3y	39.2%
Financial leverage		4.66×	EPS CAGR 3y	63.4%
= ROE		102%	FCF CAGR 3y	84.1%

THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

SHAREHOLDER RETURN PROFILE live

BUYBACK YIELD 0.58%	DIVIDEND YIELD 0.53%	TOTAL SHAREHOLDER RETURN 1.12% cash yield	SBC / REVENUE 0.8% dilution pressure
-------------------------------	--------------------------------	--	---

27 MULTIPLE HISTORY — FY SNAPSHOTS + TTM live ratio engine



28 PEER COMPARISON live peer engine

COMPANY	MKT CAP	P/E	ROE	NET MARGIN	REV GROWTH	PIOTROSKI	1-YR RET
JNJ	\$615.9B	38.7	26%	21.9%	+8.1%	7/9	+33.9%
ABBV	\$504.4B	80.4	-206%	21.3%	+10.4%	7/9	+25.8%
MRK	\$360.1B	115.8	7%	-8.0%	+4.5%	4/9	+75.4%
NVS	\$286.3B	22.9	31%	22.7%	+0.8%	5/9	+15.1%
AZN	\$256.5B	24.7	22%	16.3%	+8.6%	9/9	—
AMGN	\$233.8B	26.7	91%	23.6%	+9.2%	8/9	—
GILD	\$193.7B	-60.1	-21%	—	+5.5%	5/9	—
PFE	\$168.6B	39.1	5%	-1.6%	-0.2%	7/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

29 ANALYST CONSENSUS & ESTIMATES live consensus

Buy

45 Analysts



MEAN TARGET (QTR) \$1342.90 10 targets	TARGET VS. PRICE +6.8% last-quarter mean	NEXT REPORT 2026-10-29 street \$5.65
---	---	---

CONSENSUS ESTIMATES	REVENUE MEAN	HIGH / LOW	EPS MEAN	HIGH / LOW	# EPS EST.
FY2026	\$88.74B	\$91.42B / \$87.11B	\$34.97	\$37.56 / \$32.88	16
FY2027	\$102.67B	\$105.14B / \$98.09B	\$47.35	\$50.67 / \$44.10	16
FY2028	\$114.85B	\$129.06B / \$102.48B	\$54.14	\$63.66 / \$47.01	11

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

30 STREET TARGETS & THIRD-PARTY RATING

live targets + composite

Street Price Target — Trajectory

WINDOW	AVG TARGET	VS. PRICE	# TARGETS
Last Month	\$1435.00	+14.2%	2
Last Quarter	\$1342.90	+6.8%	10
Last Year	\$1275.04	+1.4%	54
All Time	\$890.68	-29.1%	134

Rolling mean of published targets vs. last close \$1257.03. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating


B

DCF3/5ROE5/5ROA5/5DEBT/EQ1/5P/E1/5P/B1/5

Independent quant composite as of 2026-10-16; components scored 1-5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

31 PRICE PERFORMANCE — INDEXED, 12 MO

live prices · benchmark + sector + peer set



All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL CHART — 6-MONTH DAILY CANDLES, INDICATORS ON site chart, print edition



Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

MOVING AVERAGE RIBBON & TREND site technicals-tab chart, live indicator history



MOVING AVERAGE	VALUE	DISTANCE	% DISTANCE	SIGNAL
SMA 20	\$1178.76	+78.27	+6.64%	Above
SMA 50	\$1180.17	+76.86	+6.51%	Above
SMA 200	\$1079.47	+177.56	+16.45%	Above
EMA 9	\$1205.28	+51.75	+4.29%	Above
EMA 21	\$1184.94	+72.09	+6.08%	Above
EMA 50	\$1172.97	+84.06	+7.17%	Above
EMA 200	\$1085.43	+171.60	+15.81%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

32 TECHNICAL POWER SCORE

EDGE · site engine · 90/100 composite

TECHNICAL VERDICT

BULLISH

Power Score +80

22 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%

Momentum 25%

Volume 20%

Volatility 10%

Patterns 15%


100

100


88

100

50



Indicator Vote Grid						22 bull / 0 bear	
● Price vs SMA 20	\$1178.76	● Price vs SMA 50	\$1180.17	● Price vs SMA 200	\$1079.47		
● EMA 9/21 Cross	1205.3/1184.9	● SMA 50/200	Golden	● ADX Direction	ADX 23		
● Supertrend	\$1153	● Parabolic SAR	\$1139	● SMA Slope	5.200		
● RSI	68.6	● Stochastic K/D	87/75	● StochRSI K/D	100/86		
● Williams %R	-13	● CCI	277	● TSI vs Signal	15.9		
● CMO	37.1	● ROC	9.99%	● OBV Signal	Accum		
● Chaikin MF	0.020	● MFI	57	● Force Index	34M		
● Elder Ray Bull	89.62						



33 KEY LEVELS & VOLATILITY				live indicator table
LEVEL	VALUE	LEVEL	VALUE	
Pivot / R1 / R2	\$1252.72 / \$1274.77 / \$1297.94	S1 / S2	\$1229.55 / \$1207.50	
Bollinger (20,2)	\$1118.53 – \$1238.99	Squeeze	Off	
52-wk range	\$782.70 – \$1292.65	Off 52-wk high	-2.8%	
ATR (14)	\$35.80 (2.8%)	Historical vol	26.6%	

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

34

SEASONALITY — 20-YEAR AVERAGES

live model · win rates shown

+1.3%	-0.0%	+2.1%	+1.7%	+1.8%	+3.1%	+0.6%	+1.8%	+0.5%	-1.3%	+3.3%	+4.1%
Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
50%	45%	67%	55%	60%	70%	50%	55%	60%	50%	75%	60%

Sample: 20 years — treat short histories as suggestive, not statistical.

35

RISK INDICATORS

computed from live price history

COMPUTED FROM LIVE WEEKLY PRICES	LLY	S&P 500
Weekly volatility (σ , 1y)	4.50%	1.83%
Best / worst week (1y)	+11.0% / -8.3%	—
Max drawdown (5y, monthly)	-24.5%	—
1-week VaR (95%)	-6.5%	—
Beta (5y)	0.50	1.00

36

EQUITY WEATHER & MARKET REGIME

EDGE · live weather engine

LLY EQUITY WEATHER (LIVE)

PARTLY CLOUDY · +26

Trend

Momentum

Volume

Volatility

Breadth

+43

+67

+42

-60

-30

MARKET REGIME (2026-10-16)

NEUTRAL

VIX

DOW THEORY

SPY / QQQ TSI

SECTOR STRENGTH

19.99

Confirmed Bearish


7.2 / 4.7

46/100

Normal

trend strength

breadth average



THIS SPACE INTENTIONALLY LEFT BLANK — THE NEXT SECTION BEGINS ON THE FOLLOWING PAGE

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

38 WEATHER - COMPANY VS INDUSTRY, SECTOR, UNIVERSE

EDGE · live weather engine · Partly Cloudy

OVERALL +26.0 +35.5 vs industry	TREND +43.0 +47.0 vs industry	MOMENTUM +67.0 +57.1 vs industry	VOLUME +42.1 +25.5 vs industry
--	--	---	---

READING	LLY	DRUG MANUFACTURERS - GENERAL N=150	HEALTHCARE N=5,272	ALL US SYMBOLS N=70,435
Overall	+26.0	-9.5	-24.0	-20.5
Trend	+43.0	-4.1	-25.6	-21.3
Momentum	+67.0	+9.9	-28.5	-15.8
Volume	+42.1	+16.6	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

39 EXECUTIVE COMPENSATION

live proxy data · FY2025

EXECUTIVE	TOTAL COMP	STRUCTURE
David A. Ricks Chair, President, and Chief E	\$36.7M	81% equity+incentive
Daniel M. Skovronsky, M.D., Ph.D. Executive	\$17.8M	86% equity+incentive
Anat Hakim Executive Vice President, General	\$9.8M	83% equity+incentive
Lucas Montarce Executive Vice President and	\$8.5M	85% equity+incentive
Jake Van Naarden Executive Vice President an	\$7.6M	86% equity+incentive

40 ESG ASSESSMENT

live disclosure-derived scores

PILLAR (LIVE DISCLOSURE SCORES)	SCORE
Environmental	80
Social	63
Governance	69
Composite ESG	71



41 8-K MATERIAL EVENTS

live EDGAR feed

FILED	8-K CONTENTS	ITEMS
2026-08-05	Earnings Release; Exhibits	2.02,9.01
2026-05-20	Other Events; Exhibits	8.01,9.01
2026-05-07	Shareholder Vote	5.07
2026-04-30	Earnings Release; Exhibits	2.02,9.01
2026-02-04	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-11-21	Departure/Election of Directors; Appointment of Officers	5.02
2025-10-30	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-08-20	Other Events; Financial Statements and Exhibits	8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

42 METHODOLOGY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

43 DISCLOSURES

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

44 DATA PROVENANCE FOR THIS REPORT sources · coverage · method

DATA DOMAIN	SOURCE	COVERAGE FOR THIS REPORT
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-27 to 2026-08-05
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	121 rows · 1987 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-17 to 2026-09-21
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-01-23 to 2026-07-23
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.